LH · Labcorp Holdings Inc.
$308.49
+3.89 (+1.28%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$25.11B
Shares
81.10M
Volume · Oct 2
588.22K
Avg daily vol (3M)
728.08K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$308.49
Open$305.77
Day$302.71–309.36
52W close$246.64–339.34
Avg vol 30d767K
Short int2.4M · 3.0% float · 3.3d
Short vol39%
Last earningsOct 28, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings release
Oct 28, 2026
Announced
· in 3 wks
Next earnings call
Oct 28, 2026
Scheduled
· in 3 wks
filed Aug 5, 2026
call held Jul 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$14.35B
Trailing 12 months
Net income (TTM)
$1.00B
Trailing 12 months
Revenue growth YoY
+5.8%
Year over year
Operating margin
10.4%
Trailing 12 months
P / E (TTM)
25.5
Trailing earnings · reciprocal yield 3.9%
FCF yield
4.6%
TTM · current market cap
Return on invested capital
8.5%
Trailing 12 months
Net cash
−$5.72B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.3%
Year over year · fewer shares
Price change (1Y)
+10.4%
Trailing year
Short interest
3.0%
Latest settlement · 3.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Low
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
−3%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
67%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+17%
trailing
YTD return
+23%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $319 › 200d $280 — 50d above 200d
Institutional flow
Distributing
7 of 1,051 funds reported for Sep 30 · net -240 sh shares
Insider flow
Distributing
Net -$722.5K over 90 days · 100% sells
Short interest
Rising
3.02% of float · ▲ +16.4% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,051 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
29%
expanding
EPS growth
+18%
Y/Y
Free cash flow
$1.2B
Valuation
P/E 25.6
below peers
Balance sheet
$5.1B
net debt
Quant / Vol
risk profile
Volatility
24%
annualized · 1-yr
Max drawdown
−15%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Biopharma Laboratory Services
· 2026 Guidance
$3.27B – $3.3B
Free Cash Flow
· 2026 Guidance
Non-GAAP
$1.24B – $1.36B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $319 › 200d $280 — 50d above 200d
Institutional flow
Distributing
7 of 1,051 funds reported for Sep 30 · net -240 sh shares
Insider flow
Distributing
Net -$722.5K over 90 days · 100% sells
Short interest
Rising
3.02% of float · ▲ +16.4% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,051 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $247
Now $308 · 67%
Range high $339
vs 200-day avg +10%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LH
this stock
Labcorp Holdings Inc.
|
$25.11B | +23.0% | +7.2% | 25.6 | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LH | -0.4% | -6.9% | +16.8% | +0.1% | +23.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -0.2% | -6.5% | +4.6% | -0.8% | +10.1% |
Key facts
CIK
920148
CUSIP
504922105
13F (30d)
33 filings
20 filers
Visit website
Investor relations